NOVONIX Files 6-K, Reports for December 2024

Ticker: NVNXF · Form: 6-K · Filed: Dec 26, 2024 · CIK: 1859795

Sentiment: neutral

Topics: reporting, sec-filing, foreign-private-issuer

Related Tickers: NVX

TL;DR

NOVONIX filed a 6-K for Dec 2024, confirming 20-F annual reports and listing exhibits.

AI Summary

NOVONIX Limited filed a Form 6-K on December 26, 2024, reporting for the month of December 2024. The filing indicates that NOVONIX is a foreign private issuer and will file its annual reports under Form 20-F. The document includes an exhibit index, with Exhibit 99.1 being a "Notice of Extraordina".

Why It Matters

This filing provides an update on NOVONIX's reporting status and includes an index of exhibits, signaling ongoing corporate activities and disclosures to investors.

Risk Assessment

Risk Level: low — This is a routine reporting form (6-K) that primarily confirms filing status and lists exhibits, without disclosing significant new financial or operational information.

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing by NOVONIX Limited?

The primary purpose is to report for the month of December 2024, confirm its status as a foreign private issuer filing under Form 20-F, and provide an index of exhibits.

When was this Form 6-K filed with the SEC?

This Form 6-K was filed on December 26, 2024.

What is NOVONIX Limited's principal executive office address?

NOVONIX Limited's principal executive office is located at Level 38, 71 Eagle Street, Brisbane, QLD 4000, Australia.

Does NOVONIX Limited file annual reports under Form 20-F or Form 40-F?

NOVONIX Limited indicates it files annual reports under cover of Form 20-F.

What is listed as Exhibit 99.1 in this filing?

Exhibit 99.1 is described as a 'Notice of Extraordina'.

Filing Stats: 214 words · 1 min read · ~1 pages · Grade level 13 · Accepted 2024-12-26 16:07:18

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NOVONIX LIMITED By: /s/ Dr. John Christopher Burns Dr. John Christopher Burns Chief Executive Officer Date: December 24, 2024

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing